International Clinical Trial: Best of Both (BOB) Trial: A Feasibility Study of Hybrid High Dose Rate Brachytherapy and Stereotactic Ablative Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12626001123336) titled 'Best of Both (BOB) Trial: A Feasibility Study of Hybrid High Dose Rate Brachytherapy and Stereotactic Ablative Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer' on Sept. 10.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Assignment: Single group Type of endpoint: Safety

Primary Sponsor: Peter MacCallum Cancer Centre

Condition: Prostate cancer Prostate cancer Cancer - Prostate

Intervention: This is a single arm study. All participants will receive 1 administration of high dose rate (HDR) brachytherapy and 1 fr...